A Dose of Digital: Can Pharma Make DTx a Healthy Business?
Digital therapeutics (DTx) are emerging as a potential game-changer in healthcare, offering evidence-based digital interventions to help prevent, manage, or treat specific conditions.
As pharmaceutical companies recognise the potential of DTx to improve patient outcomes, differentiate products, and generate real-world treatment data, they are increasingly seeking to incorporate these digital solutions into their business strategies.
At the same time, however, the rapid growth of the DTx sector has outpaced the ability of healthcare systems to adapt, leading to regulatory uncertainty and slow adoption rates. In this article, we explore the complex landscape of digital therapeutics and the challenges faced by DTx companies in gaining widespread adoption; we conclude by presenting Ipsos' 5-stage framework for developing a resilient and scalable DTx business.
